New Drug Therapies for Small Cell Carcinoma of the LungSchiller, J. H.PROGRESS IN RESPIRATORY RESEARCH
So, 13% of non–small cell lung cancer will harbor KRAS G12C mutations. Now we have figured out how to target those with a drug that stops the cancer from growing, and this is a mutation that has been elusive in drug development for 30 years. It's important, ...
Lumisight (pegulicianine), a newly approved fluorescent imaging drug, aids surgeons by detecting residual cancerous tissue during breast cancer surgeries, improving surgical accuracy. Anktiva (nogapendekin alfa inbakicept-pmln)was approved for patients with bacillus Calmette-Guérin (BCG)-unresponsive...
It’s the first drug to be approved for treating non–small cell lung cancer, and for the longest time, it was thought that this area that it’s targeting was undruggable,” said researcher Daniel Edi, in an interview with Pharmacy Times.“So given that it was the first one ...
Investigational New Drugsis a forum for rapid dissemination of information on new anticancer agents. The journal publishes original articles dealing with anticancer drug development. It provides the fastest possible publication of new discoveries for scientists developing anticancer agents. ...
Phase I clinical trials that treat KEAP1-mutant lung adenocarcinoma patients with a combination of CB-839 and the cancer immunotherapy drug nivolumab (Opdivo) are also underway, says Romero, who notes the MIT study might help identify patients who would be good candidates for these trials. “The...
ScienceDirect is phasing out support for older versions of Internet Explorer on Jan 12, 2016. For the best product experience, we recommend you upgrade to a newer version of IE or use a different browser: Firefox or Chrome. For additional information please see the ScienceDirect Blog page. ...
The U.S. Food and Drug Administration on Thursdayapproveda new drug to treat patients with an advanced form of deadly lung cancer. Ad Importantly, tarlatamab (Imdelltra) is only for patients who have exhausted all other options to treat extensive-stage small cell lung cancer. "The FDA's ...
The Manchester researchers tested a new drug that targets one of these molecules, MCT1, in lung cancer cells and in mouse models. Professor Caroline Dive, who led the research, said: "Small cell lung cancer has a dismal prognosis and we have seen little improvement in treatment for many yea...
About small-cell lung cancer Small-cell lung cancer is responsible for approximately 13% of lung cancer diagnoses. Patients typically have better outcomes when it is caught early, before it has spread outside the lung, but it is a fast-growing cancer and is often discovered after it has alre...